Regenerative Medical Technology Group Inc.
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equip… Read more
Regenerative Medical Technology Group Inc. (RMTG) - Net Assets
Latest net assets as of September 2025: $-30.05 Million USD
Based on the latest financial reports, Regenerative Medical Technology Group Inc. (RMTG) has net assets worth $-30.05 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.52 Million) and total liabilities ($34.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-30.05 Million |
| % of Total Assets | -664.95% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Regenerative Medical Technology Group Inc. - Net Assets Trend (2014–2024)
This chart illustrates how Regenerative Medical Technology Group Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Regenerative Medical Technology Group Inc. (2014–2024)
The table below shows the annual net assets of Regenerative Medical Technology Group Inc. from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-27.36 Million | -25.52% |
| 2023-12-31 | $-21.80 Million | -81.90% |
| 2022-12-31 | $-11.98 Million | -77.33% |
| 2021-12-31 | $-6.76 Million | -5.42% |
| 2020-12-31 | $-6.41 Million | -41.22% |
| 2018-12-31 | $-4.54 Million | -77.18% |
| 2017-12-31 | $-2.56 Million | +53.49% |
| 2016-12-31 | $-5.51 Million | +0.80% |
| 2015-12-31 | $-5.55 Million | +40.21% |
| 2014-12-31 | $-9.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Regenerative Medical Technology Group Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5354664800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.54K | % |
| Other Components | $40.18 Million | % |
| Total Equity | $-27.36 Million | 100.00% |
Regenerative Medical Technology Group Inc. Competitors by Market Cap
The table below lists competitors of Regenerative Medical Technology Group Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PCI BIOTECH ASA NK 3
F:4QG
|
$368.58K |
|
ALLIANCES DEVELOPPEMENT IMMOBILIER
BC:ALLIANCES
|
$368.79K |
|
Noble Metal Group Incorporated
V:NMG-H
|
$368.88K |
|
Formuepleje Limittellus
CO:FPILIM
|
$368.96K |
|
RANGE RESOURCES - Dusseldorf Stock Exchang
DU:RAX
|
$368.39K |
|
ISHS MSCI GER
BE:ISVP
|
$368.20K |
|
FLUOR (FLU.SG)
STU:FLU
|
$368.20K |
|
Sparinvest Bæredy Akt Akk KL A
CO:SPIBDAAKKKLA
|
$368.00K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Regenerative Medical Technology Group Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -21,795,503 to -27,356,672, a change of -5,561,169.
- Net loss of 5,562,971 reduced equity.
- Other comprehensive income increased equity by 1,050.
- Other factors increased equity by 752.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.56 Million | -20.33% |
| Other Comprehensive Income | $1.05K | +0.0% |
| Other Changes | $752.00 | +0.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Regenerative Medical Technology Group Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-37.70 | $0.03 | x |
| 2015-12-31 | $-22.54 | $0.03 | x |
| 2016-12-31 | $-3.06 | $0.03 | x |
| 2017-12-31 | $-0.74 | $0.03 | x |
| 2018-12-31 | $-1.11 | $0.03 | x |
| 2020-12-31 | $-0.69 | $0.03 | x |
| 2021-12-31 | $-0.59 | $0.03 | x |
| 2022-12-31 | $-0.98 | $0.03 | x |
| 2023-12-31 | $-1.75 | $0.03 | x |
| 2024-12-31 | $-2.18 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Regenerative Medical Technology Group Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -135.43%
- • Asset Turnover: 1.07x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.62 Million |
| 2015 | 0.00% | -35597.15% | 0.02x | 0.00x | $-1.37 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.66 Million |
| 2017 | 0.00% | -1289.31% | 3.72x | 0.00x | $-120.84K |
| 2018 | 0.00% | -4105.61% | 1.45x | 0.00x | $-1.60 Million |
| 2020 | 0.00% | -10703.47% | 0.25x | 0.00x | $-5.25 Million |
| 2021 | 0.00% | -2942.42% | 0.05x | 0.00x | $-12.21 Million |
| 2022 | 0.00% | -358.99% | 0.19x | 0.00x | $-4.30 Million |
| 2023 | 0.00% | -407.21% | 0.84x | 0.00x | $-7.63 Million |
| 2024 | 0.00% | -135.43% | 1.07x | 0.00x | $-2.83 Million |
Industry Comparison
This section compares Regenerative Medical Technology Group Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Regenerative Medical Technology Group Inc. (RMTG) | $-30.05 Million | 0.00% | N/A | $368.49K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |